Announcements Trials
Browse Landscape

Status

Terminated 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2NETWORK 1

Study Type

Observational 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Osteosarcoma 2

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × mifamurtide × Clear all
NCT01194284 2017-01-19

Surveillance Study of Patients With Newly Diagnosed Osteosarcoma

Takeda

Terminated
25 enrolled
Sarcoma

Osteosarcoma

NCT00631631 2014-05-14

Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma

Millennium Pharmaceuticals, Inc.

Completed
205 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡